TVB 2640

Drug Profile

TVB 2640

Alternative Names: TVB-2640

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3-V Biosciences
  • Developer 3-V Biosciences; Mayo Clinic; University of Kentucky; University of Texas Health Science Center at San Antonio
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Astrocytoma; Breast cancer
  • Phase I/II Metabolic syndrome
  • Phase I Colorectal cancer
  • No development reported Solid tumours

Most Recent Events

  • 18 Dec 2017 3V Biosciences and University of Missouri-Columbia completes a phase I/II trial in Metabolic syndrome in USA (PO) (NCT02948569)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Monotherapy, Second-line therapy or greater) in United Kingdom (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Monotherapy, Second-line therapy or greater) in United Kingdom (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top